A multicenter, randomized, open-label, controlled trial to evaluate the efficacy and tolerability of hydroxychloroquine and a retrospective study in adult patients with mild to moderate coronavirus disease 2019 (COVID-19)
Table 2
Proportions of negative rRT-PCR assessments on day 14 and median times to negative rRT-PCR results after randomization in the multicenter, open-label, randomized controlled trial.